-
1
-
-
33745727112
-
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
-
Wang SE, Narasanna A, Perez-Torres M, et al: HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10:25-38, 2006
-
(2006)
Cancer Cell
, vol.10
, pp. 25-38
-
-
Wang, S.E.1
Narasanna, A.2
Perez-Torres, M.3
-
2
-
-
34547470997
-
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272
-
DOI 10.1038/sj.onc.1210292, PII 1210292
-
Minami Y, Shimamura T, Shah K, et al: The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene 26:5023-5027, 2007 (Pubitemid 47172642)
-
(2007)
Oncogene
, vol.26
, Issue.34
, pp. 5023-5027
-
-
Minami, Y.1
Shimamura, T.2
Shah, K.3
LaFramboise, T.4
Glatt, K.A.5
Liniker, E.6
Borgman, C.L.7
Haringsma, H.J.8
Feng, W.9
Weir, B.A.10
Lowell, A.M.11
Lee, J.C.12
Wolf, J.13
Shapiro, G.I.14
Wong, K.-K.15
Meyerson, M.16
Thomas, R.K.17
-
3
-
-
33746154236
-
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV-G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272
-
DOI 10.1158/0008-5472.CAN-06-0971
-
Shimamura T, Ji H, Minami Y, et al: Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV-G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 66:6487-6491, 2006 (Pubitemid 44085601)
-
(2006)
Cancer Research
, vol.66
, Issue.13
, pp. 6487-6491
-
-
Shimamura, T.1
Ji, H.2
Minami, Y.3
Thomas, R.K.4
Lowell, A.M.5
Shah, K.6
Greulich, H.7
Glatt, K.A.8
Meyerson, M.9
Shapiro, G.I.10
Wong, K.-K.11
-
4
-
-
0023196582
-
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
-
Di Fiore PP, Pierce JH, Kraus MH, et al: erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178-182, 1987 (Pubitemid 17095921)
-
(1987)
Science
, vol.237
, Issue.4811
, pp. 178-182
-
-
Di, F.P.P.1
Pierce, J.H.2
Kraus, M.H.3
-
5
-
-
0023430930
-
Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells
-
Hudziak RM, Schlessinger J, Ullrich A: Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A 84:7159-7163, 1987
-
(1987)
Proc Natl Acad Sci U S A
, vol.84
, pp. 7159-7163
-
-
Hudziak, R.M.1
Schlessinger, J.2
Ullrich, A.3
-
6
-
-
0032850677
-
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
-
Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999 (Pubitemid 29415219)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.9
, pp. 2639-2648
-
-
Cobleigh, M.A.1
Vogel, C.L.2
Tripathy, D.3
Robert, N.J.4
Scholl, S.5
Fehrenbacher, L.6
Wolter, J.M.7
Paton, V.8
Shak, S.9
Lieberman, G.10
Slamon, D.J.11
-
7
-
-
0035873815
-
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
-
Seidman AD, Fornier MN, Esteva FJ, et al: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587-2595, 2001 (Pubitemid 32441364)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.10
, pp. 2587-2595
-
-
Seidman, A.D.1
Fornier, M.N.2
Esteva, F.J.3
Tan, L.4
Kaptain, S.5
Bach, A.6
Panageas, K.S.7
Arroyo, C.8
Valero, V.9
Currie, V.10
Gilewski, T.11
Theodoulou, M.12
Moynahan, M.E.13
Moasser, M.14
Sklarin, N.15
Dickler, M.16
D'Andrea, G.17
Cristofanilli, M.18
Rivera, E.19
Hortobagyi, G.N.20
Norton, L.21
Hudis, C.A.22
more..
-
8
-
-
84862914692
-
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
-
Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
-
(2012)
N Engl J Med
, vol.366
, pp. 109-119
-
-
Baselga, J.1
Cortés, J.2
Kim, S.B.3
-
9
-
-
79955515280
-
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: Mechanisms and clinical implications
-
Garrett JT, Arteaga CL: Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: Mechanisms and clinical implications. Cancer Biol Ther 11:793-800, 2011
-
(2011)
Cancer Biol Ther
, vol.11
, pp. 793-800
-
-
Garrett, J.T.1
Arteaga, C.L.2
-
10
-
-
84655162706
-
Treatment of HER2-positive breast cancer: Current status and future perspectives
-
Arteaga CL, Sliwkowski MX, Osborne CK, et al: Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat Rev Clin Oncol 9:16-32, 2012
-
(2012)
Nat Rev Clin Oncol
, vol.9
, pp. 16-32
-
-
Arteaga, C.L.1
Sliwkowski, M.X.2
Osborne, C.K.3
-
11
-
-
84859627290
-
Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
-
Gallardo A, Lerma E, Escuin D, et al: Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 106:1367-1373, 2012
-
(2012)
Br J Cancer
, vol.106
, pp. 1367-1373
-
-
Gallardo, A.1
Lerma, E.2
Escuin, D.3
-
12
-
-
80755127903
-
Mutations in the phosphatidylinositol 3-kinase pathway: Role in tumor progression and therapeutic implications in breast cancer
-
Miller TW, Rexer BN, Garrett JT, et al: Mutations in the phosphatidylinositol 3-kinase pathway: Role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13:224, 2011
-
(2011)
Breast Cancer Res
, vol.13
, pp. 224
-
-
Miller, T.W.1
Rexer, B.N.2
Garrett, J.T.3
-
13
-
-
84877028141
-
Comprehensive molecular portraits of human breast tumors
-
Cancer Genome Atlas Network
-
Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumors. Nature 490:61-70, 2012
-
(2012)
Nature
, vol.490
, pp. 61-70
-
-
-
14
-
-
4944232647
-
Lung cancer: Intragenic ERBB2 kinase mutations in tumours
-
Stephens P, Hunter C, Bignell G, et al: Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431:525-526, 2004
-
(2004)
Nature
, vol.431
, pp. 525-526
-
-
Stephens, P.1
Hunter, C.2
Bignell, G.3
-
15
-
-
20144386787
-
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas
-
DOI 10.1158/0008-5472.CAN-04-4235
-
Shigematsu H, Takahashi T, Nomura M, et al: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65:1642-1646, 2005 (Pubitemid 40478587)
-
(2005)
Cancer Research
, vol.65
, Issue.5
, pp. 1642-1646
-
-
Shigematsu, H.1
Takahashi, T.2
Nomura, M.3
Majmudar, K.4
Suzuki, M.5
Lee, H.6
Wistuba, I.I.7
Fong, K.M.8
Toyooka, S.9
Shimizu, N.10
Fujisawa, T.11
Minna, J.D.12
Gazdar, A.F.13
-
16
-
-
34250837538
-
arf expression in non-small cell lung cancers in relation to smoking history
-
DOI 10.1158/0008-5472.CAN-06-4229
-
Mounawar M, Mukeria A, Le Calvez F, et al: Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res 67:5667-5672, 2007 (Pubitemid 46984998)
-
(2007)
Cancer Research
, vol.67
, Issue.12
, pp. 5667-5672
-
-
Mounawar, M.1
Mukeria, A.2
Le, C.F.3
Hung, R.J.4
Renard, H.5
Cortot, A.6
Bollart, C.7
Zaridze, D.8
Brennan, P.9
Boffetta, P.10
Brambilla, E.11
Hainaut, P.12
-
17
-
-
15044341616
-
HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy
-
DOI 10.1016/j.lungcan.2004.10.010
-
Junker K, Stachetzki U, Rademacher D, et al: HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy. Lung Cancer 48:59-67, 2005 (Pubitemid 40381000)
-
(2005)
Lung Cancer
, vol.48
, Issue.1
, pp. 59-67
-
-
Junker, K.1
Stachetzki, U.2
Rademacher, D.3
Linder, A.4
Macha, H.-N.5
Heinecke, A.6
Muller, K.-M.7
Thomas, M.8
-
18
-
-
0242442020
-
HER2 status in non-small cell lung cancer: Results from patient screening for enrollment to a phase II study of Herceptin
-
Heinmöller P, Gross C, Beyser K, et al: HER2 status in non-small cell lung cancer: Results from patient screening for enrollment to a phase II study of Herceptin. Clin Cancer Res 9:5238-5243, 2003
-
(2003)
Clin Cancer Res
, vol.9
, pp. 5238-5243
-
-
Heinmöller, P.1
Gross, C.2
Beyser, K.3
-
19
-
-
0141456467
-
HER-2/Neu alterations in non-small cell lung cancer: A comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry
-
Pellegrini C, Falleni M, Marchetti A, et al: HER-2/Neu alterations in non-small cell lung cancer: A comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res 9:3645-3652, 2003 (Pubitemid 37169230)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.10 I
, pp. 3645-3652
-
-
Pellegrini, C.1
Falleni, M.2
Marchetti, A.3
Cassani, B.4
Miozzo, M.5
Buttitta, F.6
Roncalli, M.7
Coggi, G.8
Bosari, S.9
-
20
-
-
77950497981
-
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer
-
Burstein HJ, Sun Y, Dirix LY, et al: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28:1301-1307, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 1301-1307
-
-
Burstein, H.J.1
Sun, Y.2
Dirix, L.Y.3
-
21
-
-
58849132314
-
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy
-
Perera SA, Li D, Shimamura T, et al: HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A 106:474-479, 2009
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 474-479
-
-
Perera, S.A.1
Li, D.2
Shimamura, T.3
-
22
-
-
84860532107
-
Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy
-
García-García C, Ibrahim YH, Serra V, et al: Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res 18:2603-2612, 2012
-
(2012)
Clin Cancer Res
, vol.18
, pp. 2603-2612
-
-
García-García, C.1
Ibrahim, Y.H.2
Serra, V.3
-
23
-
-
78651458656
-
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
-
Chandarlapaty S, Sawai A, Scaltriti M, et al: AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19:58-71, 2011
-
(2011)
Cancer Cell
, vol.19
, pp. 58-71
-
-
Chandarlapaty, S.1
Sawai, A.2
Scaltriti, M.3
-
24
-
-
80655126355
-
MTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
-
Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, et al: MTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 1:248-259, 2011
-
(2011)
Cancer Discov
, vol.1
, pp. 248-259
-
-
Rodrik-Outmezguine, V.S.1
Chandarlapaty, S.2
Pagano, N.C.3
-
25
-
-
2942739164
-
A non-parametric approach to the design and analysis of two-dimensional dose-finding trials
-
DOI 10.1002/sim.1796
-
Ivanova A, Wang K: A non-parametric approach to the design and analysis of two-dimensional dose-finding trials. Stat Med 23:1861-1870, 2004 (Pubitemid 38787088)
-
(2004)
Statistics in Medicine
, vol.23
, Issue.12
, pp. 1861-1870
-
-
Ivanova, A.1
Wang, K.2
-
26
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
27
-
-
65249170861
-
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors
-
Wong KK, Fracasso PM, Bukowski RM, et al: A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 15:2552-2558, 2009
-
(2009)
Clin Cancer Res
, vol.15
, pp. 2552-2558
-
-
Wong, K.K.1
Fracasso, P.M.2
Bukowski, R.M.3
-
28
-
-
72149105604
-
Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: A case series
-
Lunardi G, Armirotti A, Nicodemo M, et al: Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: A case series. Clin Ther 31:1812-1819, 2009
-
(2009)
Clin Ther
, vol.31
, pp. 1812-1819
-
-
Lunardi, G.1
Armirotti, A.2
Nicodemo, M.3
-
29
-
-
2942735384
-
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
-
DOI 10.1200/JCO.2004.08.116
-
Raymond E, Alexandre J, Faivre S, et al: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336-2347, 2004 (Pubitemid 41115390)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.12
, pp. 2336-2347
-
-
Raymond, E.1
Alexandre, J.2
Faivre, S.3
Vera, K.4
Materman, E.5
Boni, J.6
Leister, C.7
Korth-Bradley, J.8
Hanauske, A.9
Armand, J.-P.10
-
30
-
-
77954584507
-
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non-small-cell lung cancer
-
Sequist LV, Besse B, Lynch TJ, et al: Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 28:3076-3083, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 3076-3083
-
-
Sequist, L.V.1
Besse, B.2
Lynch, T.J.3
-
31
-
-
1542398693
-
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
-
DOI 10.1200/JCO.2004.08.185
-
Atkins MB, Hidalgo M, Stadler WM, et al: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918, 2004 (Pubitemid 41103603)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.5
, pp. 909-918
-
-
Atkins, M.B.1
Hidalgo, M.2
Stadler, W.M.3
Logan, T.F.4
Dutcher, J.P.5
Hudes, G.R.6
Park, Y.7
Liou, S.-H.8
Marshall, B.9
Boni, J.P.10
Dukart, G.11
Sherman, M.L.12
-
32
-
-
84905702255
-
HER2 mutations in non-small cell lung cancer: Preliminary efficacy of targeted therapy with neratinib + torisel on a phase I trial
-
Presented at the
-
Gandhi L, Butaney M, Shaw A, et al: HER2 mutations in non-small cell lung cancer: Preliminary efficacy of targeted therapy with neratinib + torisel on a phase I trial. Presented at the World Conference on Lung Cancer, Amsterdam, the Netherlands, July 3-7, 2011
-
World Conference on Lung Cancer, Amsterdam, the Netherlands, July 3-7, 2011
-
-
Gandhi, L.1
Butaney, M.2
Shaw, A.3
-
33
-
-
0041659114
-
Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours
-
DOI 10.1046/j.1365-2559.2003.01663.x
-
Pan CC, Chen PC, Wang LS, et al: Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology 43:165-172, 2003 (Pubitemid 36963161)
-
(2003)
Histopathology
, vol.43
, Issue.2
, pp. 165-172
-
-
Pan, C.-C.1
Chen, P.C.-H.2
Wang, L.-S.3
Lee, J.-Y.4
Chiang, H.5
-
34
-
-
80051743870
-
Urothelial carcinomas: A focus on human epidermal receptors signaling
-
Grivas PD, Day M, Hussain M: Urothelial carcinomas: A focus on human epidermal receptors signaling. Am J Transl Res 3:362-373, 2011
-
(2011)
Am J Transl Res
, vol.3
, pp. 362-373
-
-
Grivas, P.D.1
Day, M.2
Hussain, M.3
-
35
-
-
79959790567
-
Discussion on the influence of HER2 status on the clinical outcome of bladder cancer continues
-
Lammers RJ, Witjes JA: Discussion on the influence of HER2 status on the clinical outcome of bladder cancer continues. Expert Rev Anticancer Ther 11:853-858, 2011
-
(2011)
Expert Rev Anticancer Ther
, vol.11
, pp. 853-858
-
-
Lammers, R.J.1
Witjes, J.A.2
-
36
-
-
34347208648
-
Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy
-
DOI 10.1016/j.ccr.2007.06.005, PII S1535610807001742
-
Li D, Shimamura T, Ji H, et al: Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12:81-93, 2007 (Pubitemid 47001787)
-
(2007)
Cancer Cell
, vol.12
, Issue.1
, pp. 81-93
-
-
Li, D.1
Shimamura, T.2
Ji, H.3
Chen, L.4
Haringsma, H.J.5
McNamara, K.6
Liang, M.-C.7
Perera, S.A.8
Zaghlul, S.9
Borgman, C.L.10
Kubo, S.11
Takahashi, M.12
Sun, Y.13
Chirieac, L.R.14
Padera, R.F.15
Lindeman, N.I.16
Janne, P.A.17
Thomas, R.K.18
Meyerson, M.L.19
Eck, M.J.20
Engelman, J.A.21
Shapiro, G.I.22
Wong, K.-K.23
more..
-
37
-
-
84905702257
-
Combined Inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer
-
Presented at the
-
Gajria D, King T, Pannu H, et al: Combined Inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 4-8, 2012
-
San Antonio Breast Cancer Symposium, San Antonio, TX, December 4-8, 2012
-
-
Gajria, D.1
King, T.2
Pannu, H.3
|